Recent Press Releases

Seattle Researchers are a Significant Step Closer to an HIV Vaccine

Research team finds a vaccine candidate that stimulates the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains SEATTLE--(BUSINESS WIRE)-- A...

ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine

LOS ANGELES, Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key...

Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint

GSK today announced that a pivotal phase III study to assess the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, has met its primary endpoint. Analysis of the...

Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related...

Sanofi Pasteur Announces FDA Approval of Fluzone® Intradermal Quadrivalent (Influenza Vaccine) for Adults

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license...

Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial

SAN DIEGO, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin®-formulated therapeutic vaccine...

FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV

The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human...

Secretary Burwell issues declaration under PREP Act to support development of Ebola vaccines

Important step in effort to develop Ebola vaccines to combat current, future outbreaks Health and Human Services Secretary Sylvia M. Burwell today announced a declaration under the Public Readiness...

VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly

Study to assess safety and immunogenicity in high-priority, at-risk population; top-line results expected in second quarter of 2015 Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate...

Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer

DPX-Survivac vaccine is a potential maintenance therapy for newly diagnosed ovarian cancer patients following initial surgery and chemotherapy; future FDA discussions to explore accelerated...

Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for...

New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma

THOUSAND OAKS, Calif. -- Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in combination with an investigational...

PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax Inc., a specialty vaccine company focused on travel and biodefense, today announced positive results from a Phase 3 safety and lot-to-lot consistency...

Powdered measles vaccine found safe in early clinical trials

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published...

Novavax (NVAX) Receives FDA Fast-Track Designation for RSV F Vaccine Candidate

Novavax (NASDAQ: NVAX) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for...

Pfizer Completes Acquisition of Baxter's Marketed Vaccines

Monday, December 1, 2014 - 7:30am EST Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines. The portfolio...

GSK statement on first phase 1 trial results of a candidate Ebola vaccine

26 November 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an...

NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response

Results from NIH Phase 1 Clinical Trial Support Accelerated Development of Candidate Vaccine An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system...

Pfizer Completes Acquisition of Baxter's Marketed Vaccines

Pfizer Completes Acquisition of Baxter's Marketed Vaccines Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.'s portfolio of marketed...

Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine

Clinical Development, Manufacturing Expertise, and Scale Critical to Success WHITEHOUSE STATION, N.J. and AMES, Iowa, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Merck (MRK), known as MSD outside the United...